Masaryk Memorial Cancer Institute

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Activity

Recent Activity

Last 14 days

Nov 4, 2026

Recruiting

Cancer Survivors Program: Effectiveness of Monitoring Adverse Events After Completion of Curative Treatment for Breast and Prostate Cancer

Nov 3, 2026

Active, not recruiting

Acupuncture for Aromatase Inhibitors-related Musculoskeletal Syndrome in Breast Cancer Patients

Oct 29, 2026

Recruiting

Monitoring of Minimal Residual Disease (MRD) in Selected Patients With Colorectal Cancer (Stages II-IV) Using Analysis of Circulating Tumor DNA (ctDNA) by the ddPCR Method

Oct 28, 2026

Recruiting

Anti-Müllerian Hormone in Breast Cancer Clinical Practice

Earlier

Oct 17, 2026TrialDetection of the BRAF V600E Mutation in Liquid Biopsy Using the CRISPR/Cas12a System

Oct 15, 2026TrialPancreatic Cancer Screening in a Population at High Risk

Aug 28, 2026TrialSequential FDG-PET and Plasma/Tissue miRNA as a Biomarkers of Preoperative Treatment Strategy in Locally Advanced Oesophago-Gastric Cancer

Jul 23, 2026TrialValidation of a New Method for Monitoring HPV Infection in Patients With Head and Neck Cancers

4 more events

Jun 27, 2026TrialA Comprehensive Preoperative and Postoperative Program Consisting Of Active Physical Therapy, A Comprehensive Nutritional Plan, And Psychological Support For Patients With Locally Advanced, Resectable Cancer Of The Esophagus, Gastroesophageal Junction, and Stomach

Jun 25, 2026TrialDetermination of Minimal Residual Disease by Deep ctDNA Sequencing.

Oct 5, 2021TrialAcupuncture as the Therapeutic Modalities of Acute Toxicity in the Radiotherapy of Head and Neck Tumors

Dec 4, 2020Trial11C-methionine in Diagnostics and Management of Glioblastoma Multiforme Patients (GlioMET)

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)